BioPharmX Corporation (NYSEMKT:BPMX)
BioPharmX Corporation is a specialty pharmaceutical company. The company focuses on the development of novel drug delivery products for women’s health, dermatology and otolaryngology markets. The Company’s product pipeline includes products in categories consists of prescription products, over-the-counter products and dietary supplements. Prescription products in development include molecular iodine pill for the treatment of breast pain associated with fibrocystic breast disease. OTC product pipeline includes a series of medicated bandages, nasal sprays and other products. Supplement product pipeline includes BioPharmX’s breast health pill. Its product candidates include BPX03 a molecular iodine tablet for the treatment of benign breast pain associated with FBC and cyclic mastalgia and BPX01 a non-lipophilic topical antibiotic for the treatment of acne. BioPharmX Corporation is headquartered in Menlo Park, California.
BioPharmX Corporation (NYSEMKT:BPMX)’s Financial Overview
BioPharmX Corporation (NYSEMKT:BPMX) surged 12.73% yesterday to close its trading session at $0.31. The company has 1 year Price Target of $3. BioPharmX Corporation has 52-Week high of $2.75 and 52-Week Low of $0.19. The stock touched its 52-Week High on Dec 11, 2015 and 52-Week Low on Nov 14, 2016. The stock traded with the volume of 1.36 Million shares yesterday. The firm shows the market capitalization of $10.17 Million.
BioPharmX Corporation (NYSEMKT:BPMX) reported its last quarterly earnings on Jul 16 where the firm reported its Actual EPS of $-0.18/share against the analyst consensus estimate of $-0.17/share. The difference between the actual and expected EPS is $-0.01 a share with a surprise factor of -5.9%.
The firm is trading with SMA20 of 16.59 Percent, SMA50 of -16.09 Percent and SMA200 of -58.76 percent. BioPharmX Corporation has P/S value of 101.74 while its P/B value stands at 0. Similarly, the company has Return on Assets of -501.3 percent, Return on Equity of 0 percent and Return on Investment of 0 Percent. The company shows Gross Margin and Operating Margin of 0 percent and 0 percent respectively.
Many brokerage firms are involved in issuing their ratings on BioPharmX Corporation (NYSEMKT:BPMX). On 15-Apr-16 Maxim Group Initiated BioPharmX Corporation Stock to Buy. Another firm also rated the stock on 7-Apr-16 where H.C. Wainwright Initiated the stock to Buy.
The Stock currently has Analyst’ mean Recommendation of 2 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 2 analysts offering 12-month price forecasts for Biopharmx Corp have a median target of 3.00, with a high estimate of 3.00 and a low estimate of 3.00. The median estimate represents a +867.74% increase from the last price of 0.31.
BioPharmX Corporation is estimated to report earnings on 12/12/2016. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates.Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 2 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.15. The reported EPS for the same quarter last year was $-0.18.
U.S. Silica Holdings, Inc. (NYSE:SLCA)
U.S. Silica Holdings, Inc. is a producer of industrial minerals, including sand proppants, whole grain silica, ground silica, fine ground silica, calcined kaolin clay and aplite clay. The company also operates as a research and development specialist for customized products and solutions. The industries and applications served by U.S. Silica includes oil and gas, glass, chemicals, foundry, building products, fillers and extenders, recreation, industrial filtration and treatment, and testing and analysis. U.S. Silica Holdings, Inc. is headquartered in Frederick, Maryland.
U.S. Silica Holdings, Inc. (NYSE:SLCA)’s Financial Outlook
The 15 analysts offering 12-month price forecasts for U.S. Silica Holdings Inc have a median target of 52.00, with a high estimate of 65.00 and a low estimate of 37.00. The median estimate represents a +2.75% increase from the last price of 50.61.
Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.
According to Zacks Investment Research, U.S. Silica Holdings, Inc. has a Consensus Recommendation of 1.58. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock gained 11.99% and closed its last trading session at $50.61. The company has the market capitalization of $3.58 Billion. The stock has 52-week high of $51.31 and 52-Week low of $13.54. The firm touched its 52-Week high on Oct 19, 2016 and 52-Week low on Feb 24, 2016. The company has volume of 6.01 Million shares. The company has a total of 70.64 Million shares outstanding.
U.S. Silica Holdings, Inc. (NYSE:SLCA) in the last quarter reported its actual EPS of $-0.13/share where the analyst estimated EPS was $-0.17/share. The difference between the actual and Estimated EPS is $0.04. This shows a surprise factor of 23.5 percent.
The company has YTD performance of 171.99 percent. Beta for U.S. Silica Holdings, Inc. stands at 2.71 while its ATR (average true range) is 2.23. The company has Weekly Volatility of 3.50%% and Monthly Volatility of 4.49%%.
U.S. Silica Holdings, Inc. has distance from 20-day Simple Moving Average (SMA20) of 10.54%, Distance from 50-Day Simple Moving Average of 8.88 percent and Distance from 200-Day Simple Moving Average of 48.82%.
The Company currently has ROA (Return on Assets) of -3.4 percent, Return on Equity (ROE) of -7.8 Percent and Return on Investment (ROI) of 4.4% with Gross margin of 13.2 percent and Operating & Profit margin of -12% and -8.7% respectively.